Haleon filed a Form 6-K on November 2 reporting the purchase of 4,492,636 ordinary shares of 0.01 pounds each, to be held as treasury shares under the buyback programme it announced on October 29, 2026, with purchases across the London Stock Exchange and other UK venues. This is routine execution of an announced programme, accession 0001654954-26-009308, not a new capital decision, and it is recorded here rather than as a full story for that reason.
Palvella Therapeutics said on October 28 that the FDA accepted its application for QTORIN, a 3.9 percent rapamycin anhydrous gel for microcystic lymphatic malformations, and granted priority review with a goal date of February 28, 2027. Acceptance is not approval. The company says 95 percent of patients aged six and older who completed the efficacy period improved on the main skin score in the single arm Phase 3 SELVA study, and that all six prespecified efficacy tests reached p below 0.001, with no drug related serious adverse event reported. The release does not print the denominator for the 95 percent figure, and the story will be told properly if and when the agency decides.
Viatris has begun its tender offer for Pacira BioSciences at 36.50 dollars a share in cash, under the deal agreed on October 8, 2026, according to the November 2 digest of the October 30 commencement announcement. The offer expires one minute after 11:59 pm Eastern on November 16, 2026 unless extended, has no financing condition, and needs more than 50 percent of outstanding shares tendered for completion. Viatris said at signing that the transaction represents aggregate equity value of 1.65 billion dollars and that it expects completion by the end of 2026.
The United Kingdom government announced three public private life sciences investments on October 28 as part of Budget 2026, totalling over 1 billion pounds and backed by almost 70 million pounds of grant funding, according to a digest summary of the GOV.UK announcement: Convatec listed at over 500 million pounds over a decade for a research hub in Manchester, Vertex at over 300 million pounds for a facility in Oxford, and Kindeva at 200 million pounds in Loughborough. The figures are the governments own and have not been independently verified in this run, so this item is carried at evidence grade C.
Gene editing shares mostly rose in the week to October 30 on data at the European Society of Gene and Cell Therapy congress in Hamburg and on the FDA draft guidance for individualised genome editing products that this beat covered as a full story on October 28. Genetic Engineering News put Prime Medicine up 29 percent over five days, Beam Therapeutics up 13 percent on initial BEAM-301 data in glycogen storage disease type Ia, and Editas and Intellia each up 11 percent, while Caribou Biosciences fell nearly 21 percent as its strategic review slide continued. The guidance remains in draft, with public comment open through November 27.
Helsinn said on October 29 that the MHRA has approved an oral suspension formulation of Akynzeo (netupitant and palonosetron) for adults, for prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, following the European Commission authorisation earlier this year. Chugai Pharma Europe is Helsinns UK and Ireland commercial partner. It is a formulation approval, not a new medicine, and no separate MHRA notice was found in the digest reporting.
Two earnings prints frame the week ahead rather than todays news. Vertex reports third quarter results after the close on November 2, with consensus near 3.42 billion to 3.43 billion dollars of revenue and earnings per share of about 4.75 to 4.80 dollars, against full year guidance of 13.1 billion to 13.2 billion dollars set at the second quarter. Amgen reports after the close on November 3. Both are expectations and company scheduling, not results, and any guidance change will be covered when the companies report.